867338-58-7

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 2450-71-7 Propargylamine 
• 15430-52-1 prop-2-yn-1-amine hydrochloride 

Downstream Products

• 959771-44-9 N-(2,4-dimethoxybenzyl)-N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide 
• 1338811-35-0 N-(2,4-dimethoxybenzyl)-3-(4-nitrophenyl)prop-2-yn-1-amine 
• 959832-98-5 5-(3-(2,4-dimethoxybenzylamino)prop-1-ynyl)-2-fluorobenzonitrile 
• 1338811-18-9 4-bromo-N-(3-(3-cyano-4-fluorophenyl)prop-2-ynyl)-N-(2,4-dimethoxybenzyl)-1H-pyrrole-2-carboxamide 
• 1338811-19-0 5-((2-(2,4-dimethoxybenzyl)-1-oxo-7-(pyridin-4-yl)-1,2-dihydropyrrolo[1,2-a]pyrazin-4-yl)methyl)-2-fluorobenzonitrile 
• 1338811-32-7 4-bromo-N-(2,4-dimethoxybenzyl)-N-(3-(4-nitrophenyl)prop-2-ynyl)-1H-pyrrole-2-carboxamide 
• 1338811-36-1 7-bromo-2-(2,4-dimethoxybenzyl)-4-(4-nitrobenzyl)pyrrolo[1,2-a]pyrazin-1(2H)-one 
• 1338811-37-2 2-(2,4-dimethoxybenzyl)-4-(4-nitrobenzyl)-7-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrrolo[1,2-a]pyrazin-1(2H)-one 
• 1338811-38-3 4-(4-aminobenzyl)-2-(2,4-dimethoxybenzyl)-7-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrrolo[1,2-a]pyrazin-1(2H)-one 
• 1338811-39-4 4-(4-aminobenzyl)-2-(2,4-dimethoxybenzyl)-7-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrrolo[1,2-a]pyrazin-1(2H)-one 
• 1594103-27-1 6-chloro-N-(2,4-dimethoxybenzyl)-N-(prop-2-yn-1-yl)pyridazine-3-carboxamide 
• 959771-71-2 5-{(E)-[6,7-dichloro-2-(2,4-dimethoxybenzyl)-1-oxo-2,3-dihydropyrrolo[1,2-a]pyrazin-4(1H)-ylidene]methyl}-2-fluorobenzonitrile 
• 959771-58-5 4-chloro-N-[3-(3-cyano-4-fluorophenyl)prop-2-yn-1-yl]-N-(2,4-dimethoxybenzyl)-1H-pyrrole-2-carboxamide 
• 959771-45-0 N-[3-(3-cyano-4-fluorophenyl)prop-2-yn-1-yl]-N-(2,4-dimethoxybenzyl)-1H-pyrrole-2-carboxamide 

Relevant academic research and scientific papers

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

An expeditious and atom-economic synthesis of lead-like, medicinally important 4,5-dihydropyrazolo[1,5-a]pyrazin-6-ones

We have developed an expeditious and atom-economic synthesis of lead-like, privileged 4,5-dihydropyrazolo[1,5-a]pyrazin-6-ones, which is based on Sonogashira coupling and a two-step condensation with hydrazine hydrate leading to two ring-forming events, with full control over the two elements of diversity present.

PYRROLOPYRAZINONE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, Y, Z, n, and m are defined in the description. The present invention relates also to compositions cont

PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP)

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP- ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

Efficient route to C2 symmetric heterocyclic backbone modified cyclic peptides

(Chemical Equation Presented) A tandem dimerization-macrocyclization approach using 1,3-dipolar azide-alkyne cycloaddition reactions has been employed in the facile and convergent solution phase syntheses of C2 symmetric cyclic peptide scaffold